Nature publishes positive pancreatic cancer Ph 1b data for NP137
Patrick Mehlen, PhD, Chief Executive Officer of NETRIS Pharma, said: “While this is only a Phase 1b trial, we are thrilled to observe the strong PFS and OS being achieved in the neogenin-high PDAC patients in LAPNET-01; we are eager to confirm these results in a larger study. This marks the third Nature publication outlining the compelling scientific and mechanistic rationale for our anti-netrin1 strategy. LAPNET-01 data strongly support the clinically meaningful potential of targeting the netrin-1 / EMT axis to overcome the development of treatment resistance by PDAC, especially in neogeninhigh patients. These exciting positive data will accelerate further development of NP137, the first-in-class anti-netrin1 monoclonal antibody. We are engaging with US and EU regulatory authorities as we design the development pathway for NP137 to treat PDAC and other solid tumors.”
Share:
More News
“Pancreatic cancer has historically been one of the most difficult-to-treat cancers and people whose tumors harbor a KRAS G12C mutation face limited options once their disease progresses,” said Jacob Van Naarden, executive vice president, and president of Lilly Oncology. “This Breakthrough Therapy designation reflects the early potential we’re seeing with
“This financing reflects the confidence our investors and strategic partners have in the progress we have made to date and the opportunities that lie ahead,” said Dr. Jack Hoppin, Chief Executive Officer of Ratio Therapeutics. “As we march the ATLAS trial forward and prepare for our 5th IND filing, these
“We are excited to initiate monotherapy expansion evaluating IDE892 in MTAP-deleted PDAC and NSCLC. We designed IDE892 to be a potential best-in-class PRMT5 inhibitor, including approximately 1,400-fold selective MTA-PRMT5 cooperative binding versus SAM-PRMT5 cooperative binding, lack of brain penetrance, and favorable drug-like properties intended to maximize its therapeutic window as
“The data presented at ASCO provided important insight into the potential clinical path for CRB-701 in 2L oropharyngeal cancer, a distinct tumor-type that is on the rise due to HPV infections,” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. “Unfortunately, current treatment options have shown limited efficacy underscoring the